Lakefront Biotherapeutics (LKFT) Change in Receivables (2016 - 2020)

Lakefront Biotherapeutics (LKFT) has reported Change in Receivables for 5 consecutive years, with -$53.1 million the latest figure, recorded in Q2 2020.

• Quarterly Change in Receivables fell 236.63% year-over-year to -$53.1 million in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $17.4 million (down 45.35% YoY) and the FY2025 annual result came in at $98.5 million, up 378.82% from the prior year.
• Change in Receivables declined to -$53.1 million in Q2 2020 per LKFT's latest filing, from $31.4 million in the prior quarter.
• Over the last five years, Change in Receivables for LKFT reached as high as $3.2 billion in Q3 2017 and fell as low as -$3.2 billion in Q2 2017.
• A 5-year average of $667665.6 and a median of -$7.3 million in 2016 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2017 — Change in Receivables tumbled 45244.97% — and 2019, when it soared 2711.82%.
• Year by year, Change in Receivables stood at -$7.1 million in 2016, then slumped by 134.91% to -$16.7 million in 2017, then jumped by 123.09% to $3.9 million in 2018, then jumped by 2711.82% to $108.6 million in 2019, then slumped by 148.88% to -$53.1 million in 2020.
• According to Business Quant data, Change in Receivables over the past three periods registered -$53.1 million, $31.4 million, and $108.6 million for Q2 2020, Q1 2020, and Q4 2019 respectively.